4SC AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
December 19, 2019 at 05:15 am EST
Share
DGAP Preliminary announcement financial reports: 4SC AG
/ Preliminary announcement on the disclosure of financial statements
4SC AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
19.12.2019 / 11:12
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
4SC AG hereby announces that the following financial reports shall be disclosed:
Report Type: Annual financial report
Language: German
Date of disclosure: March 25, 2020
Address: http://www.4sc.de/investoren/investoren-informationen/finanzberichte/
Language: English
Date of disclosure: March 25, 2020
Address: http://www.4sc.com/investors/investor-information/financial-reports/
Report Type: Financial report (half-year/Q2)
Language: German
Date of disclosure: August 11, 2020
Address: http://www.4sc.de/investoren/investoren-informationen/finanzberichte/
Language: English
Date of disclosure: August 11, 2020
Address: http://www.4sc.com/investors/investor-information/financial-reports/
19.12.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Companyâs product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
4SC AG 
